Neogen Corp (NEOG) FinancialsNEOGNeogen Corp

Neogen Corporation (NEOG) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Culture Media & Other, accounting for 38.4% of total sales, equivalent to $85.60M. Other significant revenue streams include Bacterial & General Sanitation and Genomics Services. Understanding this composition is critical for investors evaluating how NEOG navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Neogen Corporation maintains a gross margin of 37.03%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -0.81%, while the net margin is -5.34%. These profitability ratios, combined with a Return on Equity (ROE) of -2.67%, provide a clear picture of how effectively NEOG converts its operational activities into shareholder value.

In the context of the broader market, NEOG competes directly with industry leaders such as TMDX and CELC. With a market capitalization of $2.65B, it holds a significant position in the sector. When comparing efficiency, NEOG's gross margin of 37.03% stands against TMDX's 59.59% and CELC's N/A. Such benchmarking helps identify whether Neogen Corporation is trading at a premium or discount relative to its financial performance.

Neogen reported a Q4 net loss of $11.3 million, a significant improvement from a loss of $612.2 million the previous year, indicating a marked financial recovery. The gross margin remains stable at around 37%, which supports ongoing operational efficiency.